EUFAN F.C. Tablet

Symptomatic control of cough due to upper respiratory inflammation, acute bronchitis, pneumonia.

Dosage & Administration

Adult: 1-2 tablets tid.

Children 8-14 yr: 1 tablet tid.

Infrequently, change in glucose tolerance, dizziness, drowsiness, dry mouth, nausea, vomiting.

Rarely, malaise, tachycardia, palpitation, hot flushes.

No teratogenic changes were detected in rats and mice. Administration of dimemorfan in the late stage of pregnancy in mice and rats did not affect dams and fetuses. No decrease in beta granules was found by histologic observation of the pancreas in rat neonates.

Like codeine and dextromethorphan, the toxicity of dimemorfan appeared to be associated with central excitatory effects, but dimemorfan showed a better safety margin and was not teratogenic.

Diabetes mellitus.

The antitussive action of dimemorfan appears to be directly on the cough center in the medulla. Dimemorfan does not induce any significant physical or psychological dependence, and its antitussive action is not affected by the opioid receptor blocker levallorphan. Dimemorfan is therefore considered as a non-narcotic antitussive. In contrast to the narcotic antitussive, dimemorfan caused no serious problems with the digestive system, such as constipation and disorder of the bile duct, and caused no dependence or tolerance, and was unlikely to have clinical analgesic effects.